RECENT SCHOLAR PUBLICATIONS
- Elevated lipoprotein (a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study fromP Welsh, A Al Zabiby, H Byrne, HR Benbow, T Itani, G Farries, ...Atherosclerosis 389, 117437 2024
- EPH58 The Risk of First and Recurrent Mace Associated with Elevated Lp (A) in a Primary Prevention PopulationH Benbow, A Al Zabiby, H Byrne, M CostaValue in Health 26 (12), S213 2023
- Increased Risk of Major Adverse Cardiovascular Events Attributed to Lipoprotein (a) Across Current Atherosclerotic Cardiovascular Disease Risk CategoriesH Benbow, A Al Zabiby, X Hu, H Byrne, M Costa-ScharplatzCirculation 148 (Suppl_1), A14601-A14601 2023
- Review on clinical strategies for managing patients with elevated Lp (a): Cost-effectiveness of Lp (a) testing and awareness of lifestyle changes via Public Health Policy inP Orfanos, X Hu, G Montgomery, C Abbas, L Lymperopoulou, N Bennett, ...European Journal of Cardiovascular Nursing 22 (Supplement_1), zvad064. 121 2023
- The burden of coronary revascularization associated with lipoprotein(a) in patients with atherosclerotic cardiovascular disease: data from the UK BiobankNS P Welsh, H Byrne, M Costa-Scharplatz, A F Fonseca, T Itani, G Farries, A ...European Heart Journal 43 (Issue Supplement_2) 2022
- The association of lipoprotein(a) with mace including coronary revascularisations in patients with atherosclerotic cardiovascular disease: Data from UK BiobankNS P.I. Welsh, R. Brown, A.F. Fonseca, G.Farries, T.Itani, A. Al Zabiby, S ...Atherosclerosis 355, Page 41 2022
